BOSTON, MA - JUNE 6, 2019: Steven Pearson, President of the Institute for Clinical and Economic Review (ICER), talks with chief medical officer David Rind during a meeting at their offices in Boston. ...

Much of the biopharmaceutical industry this week is focused on the J.P. Morgan Healthcare Conference (JPM), where business leaders are investing in science and technologies with the potential to ...

With costs of care being more closely scrutinized, there has been a proliferation of value frameworks to help guide decision making for treatments. In a blog post for Health Affairs, Robert W. Dubois, ...

Most health plans aren't using value frameworks to decide which prescription drugs they will cover, or how much to pay for them. That's according to a new report from Washington, D.C.-based health ...

With value frameworks still in their infancy, Michael Kolodziej, MD, national medical director for oncology strategy at Aetna, doesn't see how his company can use them just yet. In fact, these ...

Rising health care costs and pharmaceutical prices in particular are among the main factors that have prompted a steady flow of scholarly and lay press articles about moving from paying for volume to ...

“Value” — especially in the context of healthcare and medicine — is a word that gets used so often these days, and in so many different ways, that it can be difficult to pin down exactly what it means ...

We spend 18 percent of our national gross domestic product on health care. As health care spending continues to grow and as we appropriately drive the health care system toward a payment system that ...

Changing the Natural History of Non–Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade Over a recent 15-year span, the price of new cancer therapies ...

Defining the value of a drug in relation to its cost has become a rapidly emerging theme in the cancer field, and several frameworks have emerged in the last year or so to help oncologists grapple ...